研究单位：[1]University of Oxford[2]The First Affiliated Hospital of Kunming Medical College Kunming,Yunnan,China,650032[3]The Second Affiliated Hospital of Kunming Medical College Kunming,Yunnan,China,650101[4]People's Hospital of Yuxi City Yuxi,Yunnan,China,653100[5]The First Affiliated Hospital of Anhui Medical University Hefei,Anhui,China,230032[6]China,Anhui The First Affiliated Hospital of Anhui Medical University Hefei,Anhui,China,230032 China,Beijing Beijing Chuiyangliu Hospital Beijing,Beijing,China,100022[7]China Meitan General Hospital Beijing,Beijing,China,100028[8]Beijing Anzhen Hospital of The Capital University of Medical Sciences Beijing,Beijing,China,100029[9]China-Japan Friendship Hospital Beijing,Beijing,China,100029[10]Peking University First Hospital Beijing,Beijing,China,100034
研究目的：
The purpose of this study is to determine whether acarbose therapy can reduce cardiovascular-related morbidity and mortality in patients with impaired glucose tolerance (IGT) who have established coronary heart disease (CHD) or acute coronary syndrome (ACS). A secondary objective of the study is to determine if acarbose therapy can prevent or delay transition to type 2 diabetes mellitus (T2DM) in this patient population.
